Navigation Links
InterMune to Present Abstracts on HCV Protease Inhibitor ITMN-191 and HCV Development Program at the EASL Meeting
Date:3/18/2009

BRISBANE, Calif., March 18 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN) today announced that five abstracts from clinical and in-vitro studies of ITMN-191 (R7227) and the company's research programs related to the hepatitis C virus (HCV) have been accepted for presentation at the 44th Annual Meeting of the European Association for the Study of the Liver (EASL, April 22-26, 2009 in Copenhagen, Denmark). The abstracts are expected to be available at www.easl.ch. ITMN-191 is an HCV NS3 protease inhibitor, being developed in collaboration with Roche.

Dan Welch, Chairman, Chief Executive Officer and President of InterMune, said, "Collectively, these abstracts demonstrate that ITMN-191 is a promising, potent antiviral compound for the treatment of HCV and underscore our company's continued progress in the research of new compounds for HCV patients."

Presentations of ITMN-191 Clinical Results

  • Antiviral Activity and Safety of ITMN-191 in Combination with Peginterferon alfa-2a and Ribavirin in Patients with Chronic Hepatitis C Virus (HCV).
  • Incidence of Virologic Escape Observed During ITMN-191 Monotherapy is Genotype Dependent, Associated with a Specific NS3 Substitution, and Suppressed Upon Combination with Peginterferon alfa-2a/Ribavirin.

Additional InterMune Presentations at EASL

Titles of additional InterMune posters to be presented at EASL are as follows:

  • Combination of the NS3/4A Protease Inhibitor ITMN-191 with the Allosteric NS5B Polymerase Inhibitor ITMN-8020 Enhances Replicon Clearance and Reduces the Emergence of Drug Resistant Variants.
  • Discovery of Potent, Bio
    '/>"/>

SOURCE InterMune, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. InterMune Reports Fourth Quarter and Full Year 2008 Financial Results and Business Highlights
2. InterMune to Release Fourth Quarter, Full Year 2008 Financial Results on February 26
3. InterMune Announces Issuance of U.S. Patent for ITMN-191
4. InterMune Announces Pricing of Public Offering of 3,500,000 Shares of Common Stock
5. InterMune Reports Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF
6. InterMune to Present at J.P. Morgan Healthcare Conference
7. InterMune to Present at Deutsche Bank Biotech Boston Confab
8. InterMune Reports Third Quarter 2008 Financial Results and Business Highlights
9. InterMune to Release Third Quarter 2008 Financial Results on November 6
10. InterMune Reports Japanese Regulatory Approval of Pirfenidone in IPF
11. InterMune to Present Four Abstracts on HCV Protease Inhibitor ITMN-191 at the AASLD Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... Crystal Diagnostics (CDx) Xpress System, a rapid ... AOAC-PTM Certifications for the six non-O157 Shiga toxin-producing E. coli ... to as STEC or the “Big-6”) as well as Escherichia ... per 325 g of raw ground beef and raw beef ...
(Date:1/22/2015)... 22, 2015 Controlled Substance Compliance Services ... helps companies check the legal requirements around using controlled ... China. , As their international operations expand and ... software solutions built as a result of the first ...
(Date:1/22/2015)... , Jan. 22, 2015   Cypher Genomics, Inc., ... Inc. (NASDAQ: SQNM ), the leading ... for next generation noninvasive prenatal tests (NIPT). Through ... technology, called Mantis™, to advance analysis of clinically-relevant ...
(Date:12/25/2014)... The report “Service Quality Management and ... Provider Type - Global Advancements, Worldwide Forecasts & Analysis ... analysis and forecasting of revenues. , Browse 152 ... and in-depth TOC on “Service Quality Management (SQM) and ...
Breaking Biology Technology:Crystal Diagnostics Awarded AOAC-PTM Accreditation for the Rapid Detection of “Big 6” E.coli Food Pathogens 2Global Compliance Service for Controlled Substances to Expand to China 2Cypher Genomics and Sequenom Announce Development Agreement 2Cypher Genomics and Sequenom Announce Development Agreement 3Cypher Genomics and Sequenom Announce Development Agreement 4Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 2Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 3Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 4
... DUBLIN and PHILADELPHIA , June 3, ... specialty biopharmaceutical company,announces that its subsidiary Shire LLC has filed a lawsuit ... Anchen Pharmaceuticals,Inc. and Anchen, Inc. (collectively "Anchen") for the infringement of U.S.,Patent ... patent). , , , ...
... , -Proceeds to support acceleration of CYT387 Phase II myelofibrosis study- , ... MISSISSAUGA, ON , June 3 ... raised approximately US$3.2 million through a non-brokered private placement of 2,500,000 ... at no discount to the closing price of the shares on the NYSE ...
... , , , ... Endpoints , , , ... Agency in,2010 , , , ... reproductive medicine, announces positive Phase III data from its,second pivotal study (PEARL I) for its lead product ...
Cached Biology Technology:INTUNIV(TM) - Shire Files Suit Against Anchen Pharmaceuticals, Inc. and Anchen, Inc. 2INTUNIV(TM) - Shire Files Suit Against Anchen Pharmaceuticals, Inc. and Anchen, Inc. 3YM BioSciences raises US$3.2 million in support of JAK 1/2 program 2YM BioSciences raises US$3.2 million in support of JAK 1/2 program 3YM BioSciences raises US$3.2 million in support of JAK 1/2 program 4PregLem Announces Positive Phase III Results for Esmya(TM) 2PregLem Announces Positive Phase III Results for Esmya(TM) 3PregLem Announces Positive Phase III Results for Esmya(TM) 4
(Date:1/22/2015)... POINT ROBERTS, Washington , January 20, 2015 ... sectors including technology and tech stocks, releases video from the ... pickpocket and security consultant Apollo Robbins . ... about the Wocket™ biometric smart wallet, a product of NXT-ID, ...
(Date:1/22/2015)... 2015 , Europe,s ... The European Patent Office to present a video retrospective of the ... be featured: Christofer Toumazou and Sophie Wilson   ... winners of the Award   Starting on 22 January ...
(Date:1/22/2015)... Inc. , a market leader of iris-based identity authentication solutions, ... the new role of Senior Vice President of Mobile and ... platforms and wearable solutions for EyeLock,s technologies. Gerber brings more ... industry to his role at EyeLock, with expertise in human ...
Breaking Biology News(10 mins):Apollo Robbins Talks about the Illusion of Personal Safety and How Easily Your Wallet is Stolen; If a Wocket Wallet is Stolen the Thief Can't do Anything With it! 2Apollo Robbins Talks about the Illusion of Personal Safety and How Easily Your Wallet is Stolen; If a Wocket Wallet is Stolen the Thief Can't do Anything With it! 3Ten Years of the European Inventor Award: A Retrospective Look at the Inventors and Ideas That Have Changed Our Lives 2Ten Years of the European Inventor Award: A Retrospective Look at the Inventors and Ideas That Have Changed Our Lives 3EyeLock Names Steve Gerber as Senior Vice President of Mobile and Wearables 2
... PITTSBURGH, Feb. 4 Researchers at the University ... $5.6 million federal contract to pursue the continued development ... and small children with congenital or acquired heart disease. ... sophisticated technologies that have saved the lives of older ...
... that the hydrodynamic environment of fish can shape their physical ... Journal of Experimental Biology Web site, was sponsored by ... Catch a glimpse of a fish,s body shape, and you ... look as if they should outpace frilly reef fish and ...
... energy habits and provide immediate feedback on consumption could ... compromising comfort. The new energy-saving ,Wattbox, device is ... improvements supported by a 2.1 million grant from the ... As well as working with standard energy supplies, the ...
Cached Biology News:Pitt-led team gets $5.6 million contract for heart assist device for infants and toddlers 2Pitt-led team gets $5.6 million contract for heart assist device for infants and toddlers 3Research finds water movements can shape fish evolution 2Habit-learning device will lower energy bills under new clean energy cashback scheme 2
... Origami host strains are K-12 derivatives that ... (trxB) and glutathione reductase (gor) genes, which ... cytoplasm. Studies have shown that expression in ... in another host even though overall expression ...
... Zero Blunt TOPO PCR ... is designed for cloning ... blunt-end PCR products. The ... TOPO Cloning and greater ...
... CELLection Dynabeads (4.5 m) coated with the ... EpCAM and DNase Releasing Buffer. For ... tumour cells directly from blood, bone marrow ... enriched from bone marrow. Enriched cells are ...
Recombinant Human CCL21/6Ckine (Mucin Stalk Chimera)...
Biology Products: